目的 探討四季抗病毒合劑聯(lián)合重組人干擾素α1b注射液治療小兒上呼吸道感染的臨床療效。方法 選取2015年1月-2016年1月成都市金牛區(qū)婦幼保健院兒科收治的上呼吸道感染患兒86例,根據(jù)治療方案的不同分為對照組和治療組,每組各43例。對照組患兒霧化吸入重組人干擾素α1b注射液,1~2歲5μg/次,2~6歲10μg/次,6~7歲20μg/次,加入生理鹽水4mL,15min/次,2次/d。治療組在對照組治療基礎上口服四季抗病毒合劑,1~5歲5mL/次,5~7歲7.5mL/次,3次/d。兩組患兒均連續(xù)治療5d。觀察兩組的臨床療效,同時比較兩組患兒退熱時間、咳嗽消失時間、咽喉疼痛消失時間。結果 治療后,對照組和治療組的總有效率分別為86.05%、93.02%,兩組比較差異具有統(tǒng)計學意義(P<0.05)。治療組患兒退熱時間、咳嗽消失時間以及咽喉疼痛消失時間均明顯短于對照組,兩組比較差異有統(tǒng)計學意義(P<0.05)。結論 四季抗病毒合劑聯(lián)合重組人干擾素α1b注射液治療小兒上呼吸道感染具有較好的臨床療效,可以快速緩解患兒的臨床癥狀,不良反應少,具有一定的臨床推廣應用價值。

Objective To investigate the clinical effect of Siji Kangbingdu Mistura combined with Recombinant Human Interferon α1b Injection in treatment of children with upper respiratory tract infection. Methods Children (86 cases) with upper respiratory tract infection in Jinniu District Maternal and Child Health Care Hospital of Chengdu from January 2015 to January 2016 were enrolled in this study. According to the different treatment plans, children were divided into control group (43 cases) and treatment group (43 cases). The children in the control group were aerosol inhalation administered with Recombinant Human Interferon α1b Injection, and the 1-2 year old patients were given 5 μg/time, 2-6 year old patients were given 10 μg/time, 6-7 year old patients were given 20 μg/time, Recombinant Human Interferon α1b Injection added into normal saline 4 mL, 15 min/time, twice daily. The children in the treatment group were po administered with Siji Kangbingdu Mistura on the basis of control group, 1-5 year old patients were given 5 mL/time, 5-7 year old patients were given 7.5 mL/time, three times daily. The children in two groups were treated for 5 d. After treatment, the clinical efficacies were evaluated, and the antifebrile time, and disappearred times of cough and throat pain in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 86.05% and 93.02%, respectively, and there were differences between two groups (P < 0.05). The antifebrile time, and disappearred times of cough and throat pain in treatment group were significantly shorter than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Siji Kangbingdu Mistura combined with Recombinant Human Interferon α1b Injection has clinical curative effect in treatment of children with upper respiratory tract infection, and can relieve clinical symptoms quickly with less adverse reaction, which has a certain clinical application value.